Subcutaneous · GLP-1 / glucagon dual
SAR425899
6 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
6
Active
0
Recruiting
0
Completed
5
Sites
62
Countries
9
Endpoints
97
Composite endpoints
2
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
4
Phase 2
2
Trials by status
Completed
5
Withdrawn
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
30
Glycemic / diabetes
24
Other (unclassified)
14
Weight & body composition
13
MASH / liver
9
Cardiometabolic biomarkers
6
Cardiovascular outcomes
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
Fasting glucose, changeGlycemic
6
HbA1c, changeGlycemic
5
Body weight, absolute change (kg)Weight
5
Treatment-emergent AEs (any)Safety/PK
4
CmaxSafety/PK
4
Postprandial glucoseGlycemic
3
Waist circumference, changeWeight
3
AUC₀–∞Safety/PK
3
Half-lifeSafety/PK
3
HbA1c <6.5% achievementGlycemic
2
HOMA-IR (insulin sensitivity)Glycemic
2
TmaxSafety/PK
2
≥10% weight-loss respondersWeight
1
≥5% weight-loss respondersWeight
1
Total cholesterol, changeBiomarker
1
Free fatty acids, changeBiomarker
1
Triglycerides, changeBiomarker
1
Total fat massWeight
1
C-peptide AUCGlycemic
1
MASH resolution, no fibrosis worseningMASH
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
6 of 6